Aligos Therapeutics Reports Q2 EPS of $1.53, Misses Consensus

Aligos Therapeutics reported Q2 EPS of ($1.53) and revenue of $965,000, exceeding consensus estimates of ($2.54) and $433,330. The company's Phase 2 B-SUPREME study for ALG-000184 is underway, with regulatory approvals across several countries and dosing expected to commence soon. The Phase 1 data presented at the EASL meeting suggests that ALG-000184 has the potential to replace standard of care treatment for chronic HBV infection and may become the backbone of treatments aimed at a functional cure.

Aligos Therapeutics, Inc. (ALGS) reported a Q2 2025 loss of $1.53 per share, surpassing the Zacks Consensus Estimate of a loss of $2.35 [1]. This compares to earnings of $0.75 per share a year ago. The company also reported revenues of $0.97 million for the quarter, missing the Zacks Consensus Estimate by 3.5% [1]. These figures are adjusted for non-recurring items.

The company's Phase 2 B-SUPREME study for ALG-000184 is progressing, with regulatory approvals across several countries and dosing expected to commence soon. Phase 1 data presented at the EASL meeting suggested that ALG-000184 has the potential to replace standard of care treatment for chronic HBV infection and may become the backbone of treatments aimed at a functional cure [2].

Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once. The company's shares have lost about 80.2% since the beginning of the year versus the S&P 500's gain of 7.1% [1].

The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock. The Medical - Biomedical and Genetics industry is currently in the bottom 42% of the 250 plus Zacks industries [1].

References:
[1] https://www.nasdaq.com/articles/aligos-therapeutics-inc-algs-reports-q2-loss-misses-revenue-estimates
[2] https://www.biospace.com/press-releases/alkeus-pharmaceuticals-announces-presentation-of-positive-interim-tease-3-study-data-in-early-stage-stargardt-disease-patients-treated-with-oral-gildeuretinol